4.5 Review

Endocannabinoids and cortical plasticity: CB1R as a possible regulator of the excitation/inhibition balance in health and disease

Journal

EUROPEAN JOURNAL OF NEUROSCIENCE
Volume 55, Issue 4, Pages 971-988

Publisher

WILEY
DOI: 10.1111/ejn.15110

Keywords

cannabinoids; E; I balance; neocortex; neuroplasticity; schizophrenia

Categories

Funding

  1. KU Leuven Research Council [C14/16/048]
  2. Research Foundation Flanders (FWO), Belgium [G061216N, SB/1S62920N, SB/151597]

Ask authors/readers for more resources

The endocannabinoid system is associated with neurological disorders like schizophrenia, where CB1R signaling plays a crucial role in regulating cortical plasticity and the E/I balance. Modulation of elements such as neurons and astrocytes fine-tunes the E/I balance, impacting the pathogenesis of schizophrenia.
The endocannabinoid system has been linked to neurological disorders in which the excitation inhibition (E/I) balance in the neocortex is dysregulated, such as schizophrenia. The main endocannabinoid receptor type 1 of the central nervous system-CB1R-is expressed on different cell types, that when activated, modulate the cortical E/I balance. Here we review how CB1R signalling contributes to phases of heightened plasticity of the neocortex. We review the major role of the CB1R in cortical plasticity throughout life, including the early life sensory critical periods, the later maturation phase of the association cortex in adolescence, and the adult phase of sensory deprivation-induced cortical plasticity. Endocannabinoid-mediated long-term potentiation and depression of synapse strength fine-tune the E/I balance in visual, somatosensory and association areas. We emphasize how a distinct set of key endocannabinoid-regulated elements such as GABA and glutamate release, basket parvalbumin interneurons, somatostatin interneurons and astrocytes, are essential for normal cortical plasticity and dysregulated in schizophrenia. Even though a lot of data has been gathered, mechanistic knowledge about the exact CB1R-based modulation of excitation and/or inhibition is still lacking depending on cortical area and maturation phase in life. We emphasize the importance of creating such detailed knowledge for a better comprehension of what underlies the dysregulation of the neocortex in schizophrenic patients in adulthood. We propose that taking age, brain area and cell type into consideration when modulating the cortical E/I imbalance via cannabinoid-based pharmacology may pave the way for better patient care.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available